After finishing two full days of watching abstracts and education sessions about multiple myeloma at the American Society of Hematology Conference (ASH), my head is spinning from the number of new combinations, therapies, and therapy targets. All of this is excellent news for us, but this makes treatment decisions much more complicated. This diagram presented by Dr. […]
“Bispecifics are the prom queens of ASH”—Tom Martin, M.D. Attending the virtual iteration of ASH has been a unique experience, in that I’ve had the opportunity to see many of the leading international myeloma experts all from the comfort of own home. One of the silver linings of a virtual symposium is that I have […]
The antibodies are front and center during the 2020 American Society of Hematology’s Annual Meeting. I thought this would be a good time to review the mechanism of action (how they work) of each type of antibody. The first antibodies to make it to the myeloma scene were the monoclonal antibodies. (mAbs) Monoclonal antibodies in […]
It’s the year 2020 which is a notable year for reasons beside being a global pandemic. For me, 2020 marks my 20th year of survival with multiple myeloma. I am deeply grateful for all the research that has taken place and hopeful for the future of myeloma, all while waiting for a cure. In 2000, […]
“You have to cherish things in a different way when you know the clock is ticking…”—Chadwick Boseman I recently celebrated the ten-year anniversary of my multiple myeloma diagnosis. I remember racing to the radiology unit at 8 a.m. to review the results of my MRI. I had been on call since 7 a.m. that morning and […]
